|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: TUT4 |
Gene summary for TUT4 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | TUT4 | Gene ID | 23318 |
| Gene name | terminal uridylyl transferase 4 | |
| Gene Alias | PAPD3 | |
| Cytomap | 1p32.3 | |
| Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | A0A0C4DFM7 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 23318 | TUT4 | HTA11_3410_2000001011 | Human | Colorectum | AD | 6.96e-10 | -3.80e-01 | 0.0155 |
| 23318 | TUT4 | HTA11_2487_2000001011 | Human | Colorectum | SER | 4.17e-03 | -4.02e-01 | -0.1808 |
| 23318 | TUT4 | HTA11_83_2000001011 | Human | Colorectum | SER | 3.92e-03 | -4.73e-01 | -0.1526 |
| 23318 | TUT4 | HTA11_696_2000001011 | Human | Colorectum | AD | 2.17e-03 | -3.02e-01 | -0.1464 |
| 23318 | TUT4 | HTA11_6818_2000001021 | Human | Colorectum | AD | 2.81e-03 | -1.29e-01 | 0.0588 |
| 23318 | TUT4 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 4.51e-40 | -6.77e-01 | 0.294 |
| 23318 | TUT4 | HTA11_99999965104_69814 | Human | Colorectum | MSS | 3.78e-14 | -6.77e-01 | 0.281 |
| 23318 | TUT4 | HTA11_99999971662_82457 | Human | Colorectum | MSS | 2.28e-38 | -6.77e-01 | 0.3859 |
| 23318 | TUT4 | HTA11_99999973899_84307 | Human | Colorectum | MSS | 8.15e-11 | -6.77e-01 | 0.2585 |
| 23318 | TUT4 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 6.22e-41 | -6.77e-01 | 0.3005 |
| 23318 | TUT4 | A015-C-203 | Human | Colorectum | FAP | 1.31e-23 | -2.17e-01 | -0.1294 |
| 23318 | TUT4 | A015-C-204 | Human | Colorectum | FAP | 8.35e-04 | -2.42e-01 | -0.0228 |
| 23318 | TUT4 | A002-C-201 | Human | Colorectum | FAP | 3.62e-10 | -2.48e-01 | 0.0324 |
| 23318 | TUT4 | A002-C-203 | Human | Colorectum | FAP | 2.48e-03 | -1.33e-01 | 0.2786 |
| 23318 | TUT4 | A001-C-108 | Human | Colorectum | FAP | 2.55e-15 | -1.48e-02 | -0.0272 |
| 23318 | TUT4 | A002-C-205 | Human | Colorectum | FAP | 3.98e-15 | -1.55e-01 | -0.1236 |
| 23318 | TUT4 | A015-C-006 | Human | Colorectum | FAP | 8.06e-10 | -1.47e-01 | -0.0994 |
| 23318 | TUT4 | A015-C-106 | Human | Colorectum | FAP | 2.61e-06 | 3.24e-03 | -0.0511 |
| 23318 | TUT4 | A002-C-114 | Human | Colorectum | FAP | 1.07e-11 | -9.15e-02 | -0.1561 |
| 23318 | TUT4 | A015-C-104 | Human | Colorectum | FAP | 3.41e-26 | 3.12e-02 | -0.1899 |
| Page: 1 2 3 4 5 6 7 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:006101416 | Esophagus | ESCC | positive regulation of mRNA catabolic process | 63/8552 | 87/18723 | 3.70e-07 | 5.15e-06 | 63 |
| GO:009872714 | Esophagus | ESCC | maintenance of cell number | 90/8552 | 134/18723 | 3.94e-07 | 5.43e-06 | 90 |
| GO:006115716 | Esophagus | ESCC | mRNA destabilization | 61/8552 | 84/18723 | 4.81e-07 | 6.49e-06 | 61 |
| GO:001982714 | Esophagus | ESCC | stem cell population maintenance | 88/8552 | 131/18723 | 5.23e-07 | 6.97e-06 | 88 |
| GO:005077916 | Esophagus | ESCC | RNA destabilization | 63/8552 | 88/18723 | 7.23e-07 | 9.40e-06 | 63 |
| GO:00311233 | Esophagus | ESCC | RNA 3'-end processing | 76/8552 | 116/18723 | 1.25e-05 | 1.15e-04 | 76 |
| GO:00346613 | Esophagus | ESCC | ncRNA catabolic process | 33/8552 | 43/18723 | 3.25e-05 | 2.69e-04 | 33 |
| GO:000028816 | Esophagus | ESCC | nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay | 40/8552 | 56/18723 | 8.36e-05 | 6.08e-04 | 40 |
| GO:00351969 | Esophagus | ESCC | production of miRNAs involved in gene silencing by miRNA | 37/8552 | 52/18723 | 1.75e-04 | 1.14e-03 | 37 |
| GO:00310508 | Esophagus | ESCC | dsRNA processing | 38/8552 | 54/18723 | 2.08e-04 | 1.31e-03 | 38 |
| GO:00709188 | Esophagus | ESCC | production of small RNA involved in gene silencing by RNA | 38/8552 | 54/18723 | 2.08e-04 | 1.31e-03 | 38 |
| GO:003424914 | Esophagus | ESCC | negative regulation of cellular amide metabolic process | 144/8552 | 273/18723 | 1.08e-02 | 3.67e-02 | 144 |
| GO:00098967 | Liver | NAFLD | positive regulation of catabolic process | 108/1882 | 492/18723 | 2.68e-15 | 3.14e-12 | 108 |
| GO:00194396 | Liver | NAFLD | aromatic compound catabolic process | 102/1882 | 467/18723 | 2.29e-14 | 1.91e-11 | 102 |
| GO:19013616 | Liver | NAFLD | organic cyclic compound catabolic process | 105/1882 | 495/18723 | 7.04e-14 | 5.15e-11 | 105 |
| GO:00313317 | Liver | NAFLD | positive regulation of cellular catabolic process | 92/1882 | 427/18723 | 1.01e-12 | 4.91e-10 | 92 |
| GO:00442707 | Liver | NAFLD | cellular nitrogen compound catabolic process | 93/1882 | 451/18723 | 1.04e-11 | 4.34e-09 | 93 |
| GO:00467006 | Liver | NAFLD | heterocycle catabolic process | 92/1882 | 445/18723 | 1.16e-11 | 4.52e-09 | 92 |
| GO:19033116 | Liver | NAFLD | regulation of mRNA metabolic process | 66/1882 | 288/18723 | 1.06e-10 | 2.96e-08 | 66 |
| GO:00064026 | Liver | NAFLD | mRNA catabolic process | 56/1882 | 232/18723 | 3.49e-10 | 9.27e-08 | 56 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |